BIOLASE (NASDAQ:BIOL) PT fell to $2.00

BIOLASE (NASDAQ:BIOL – Get Free Report) The target price was decreased by stock analysts at Ascendiant Capital Markets from $3.50 to $2.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the medical technology company’s stock.

A number of other research firms have also weighed in on BIOL. StockNews.com started coverage on shares of BIOLASE in a research report on Sunday. They issued a “sell” rating on the stock. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Monday, August 12th. Finally, Maxim Group lowered shares of BIOLASE from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 24th.

Check out our latest research report on BIOLASE

BIOLASE stock performance

Shares of BIOL stock opened at $0.06 on Tuesday. The firm has a market cap of $1.95 million, a PE ratio of 0.00 and a beta of 0.71. The company’s 50-day simple moving average is $0.07 and its 200-day simple moving average is $0.12. BIOLASE has a 12 month low of $0.04 and a 12 month high of $4.23.

BIOLASE (NASDAQ:BIOL – Get Your Free Report ) last announced its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $11.56 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.

Institutional investors intervene on BIOLASE

An institutional investor recently lifted its position in BIOLASE shares. Virtu Financial LLC increased its holdings in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to the company in its most recent SEC disclosure. The firm owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of shares are owned by institutional investors and hedge funds.

BIOLASE company profile

(Get a free report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets and sells laser systems for dentists and their patients in the United States and internationally. Its dental laser systems enable dentists, periodontists, endodontists, pediatric dentists, periodontal surgeons and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative and complex surgical applications.

Featured stories

Receive news and ratings for BIOLASE daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BIOLASE and related companies with MarketBeat.com’s FREE daily email newsletter.